[1] G. Mendiratta, E. Ke, M. Aziz, D. Liarakos, M. Tong, E.C. Stites, Cancer gene mutation frequencies for the U.S. population, Nature Communications 2021 12:1 12 (2021) 1–11. https://doi.org/10.1038/s41467-021-26213-y.
[2] C. Oliveira, S. Velho, C. Moutinho, A. Ferreira, A. Preto, E. Domingo, A.F. Capelinha, A. Duval, R. Hamelin, J.C. MacHado, S. Schwartz, F. Carneiro, R. Seruca, KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression, Oncogene 2007 26:1 26 (2006) 158–163. https://doi.org/10.1038/sj.onc.1209758.
[3] L. Huang, Z. Guo, F. Wang, L. Fu, KRAS mutation: from undruggable to druggable in cancer, Signal Transduction and Targeted Therapy 2021 6:1 6 (2021) 1–20. https://doi.org/10.1038/s41392-021-00780-4.
[4] S. Velho, C. Moutinho, L. Cirnes, C. Albuquerque, R. Hamelin, F. Schmitt, F. Carneiro, C. Oliveira, R. Seruca, BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?, BMC Cancer 8 (2008) 255. https://doi.org/10.1186/1471-2407-8-255.
[5] S. Velho, K.M. Haigis, Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras, Exp Cell Res 317 (2011) 2732. https://doi.org/10.1016/J.YEXCR.2011.06.002.
[6] A.T. Boutin, W.T. Liao, M. Wang, S.S. Hwang, T. V. Karpinets, H. Cheung, G.C. Chu, S. Jiang, J. Hu, K. Chang, E. Vilar, X. Song, J. Zhang, S. Kopetz, A. Futreal, Y.A. Wang, L.N. Kwong, R.A. DePinho, Oncogenic Kras drives invasion and maintains metastases in colorectal cancer, Genes Dev 31 (2017) 370–382. https://doi.org/10.1101/GAD.293449.116/-/DC1.
[7] Y. Pylayeva-Gupta, E. Grabocka, D. Bar-Sagi, RAS oncogenes: weaving a tumorigenic web, Nature Reviews Cancer 2011 11:11 11 (2011) 761–774. https://doi.org/10.1038/nrc3106.
[8] P. Dias Carvalho, F. Martins, S. Mendonça, A. Ribeiro, A.L. Machado, J. Carvalho, M.J. Oliveira, S. Velho, Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis, Int J Cancer 151 (2022) 1810–1823. https://doi.org/10.1002/IJC.34225.
[9] T. Charitou, S. Srihari, M.A. Lynn, M.A. Jarboui, E. Fasterius, M. Moldovan, S. Shirasawa, T. Tsunoda, M. Ueffing, J. Xie, J. Xin, X. Wang, C.G. Proud, K. Boldt, C. Al-Khalili Szigyarto, W. Kolch, D.J. Lynn, Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation, Br J Cancer 121 (2019) 37–50. https://doi.org/10.1038/S41416-019-0477-7.
[10] D.M. Zocche, C. Ramirez, F.M. Fontao, L.D. Costa, M.A. Redal, Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer, Front Genet 6 (2015). https://doi.org/10.3389/FGENE.2015.00116.
[11] S. Rizzo, G. Bronte, D. Fanale, L. Corsini, N. Silvestris, D. Santini, G. Gulotta, V. Bazan, N. Gebbia, F. Fulfaro, A. Russo, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev 36 Suppl 3 (2010). https://doi.org/10.1016/S0305-7372(10)70021-9.
[12] S. Hamarsheh, O. Groß, T. Brummer, R. Zeiser, Immune modulatory effects of oncogenic KRAS in cancer, Nature Communications 2020 11:1 11 (2020) 1–11. https://doi.org/10.1038/s41467-020-19288-6.
[13] P.D. Carvalho, A.L. Machado, F. Martins, R. Seruca, S. Velho, Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors, Cancers (Basel) 11 (2019). https://doi.org/10.3390/CANCERS11122010.
[14] P.D. Carvalho, C.F. Guimarães, A.P. Cardoso, S. Mendonça, Â.M. Costa, M.J. Oliveira, S. Velho, KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment, Cancer Res 78 (2018) 7–14. https://doi.org/10.1158/0008-5472.CAN-17-2084.
[15] V. Merz, M. Gaule, C. Zecchetto, A. Cavaliere, S. Casalino, C. Pesoni, S. Contarelli, F. Sabbadini, M. Bertolini, D. Mangiameli, M. Milella, V. Fedele, D. Melisi, Targeting KRAS: The Elephant in the Room of Epithelial Cancers, Front Oncol 11 (2021). https://doi.org/10.3389/FONC.2021.638360.
[16] D.S. Hong, M.G. Fakih, J.H. Strickler, J. Desai, G.A. Durm, G.I. Shapiro, G.S. Falchook, T.J. Price, A. Sacher, C.S. Denlinger, Y.-J. Bang, G.K. Dy, J.C. Krauss, Y. Kuboki, J.C. Kuo, A.L. Coveler, K. Park, T.W. Kim, F. Barlesi, P.N. Munster, S.S. Ramalingam, T.F. Burns, F. Meric-Bernstam, H. Henary, J. Ngang, G. Ngarmchamnanrith, J. Kim, B.E. Houk, J. Canon, J.R. Lipford, G. Friberg, P. Lito, R. Govindan, B.T. Li, KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors, N Engl J Med 383 (2020) 1207–1217. https://doi.org/10.1056/NEJMOA1917239.
[17] D. Kim, L. Herdeis, D. Rudolph, Y. Zhao, J. Böttcher, A. Vides, C.I. Ayala-Santos, Y. Pourfarjam, A. Cuevas-Navarro, J.Y. Xue, A. Mantoulidis, J. Bröker, T. Wunberg, O. Schaaf, J. Popow, B. Wolkerstorfer, K.G. Kropatsch, R. Qu, E. de Stanchina, B. Sang, C. Li, D.B. McConnell, N. Kraut, P. Lito, Pan-KRAS inhibitor disables oncogenic signalling and tumour growth, Nature 2023 619:7968 619 (2023) 160–166. https://doi.org/10.1038/s41586-023-06123-3.
[18] R.J. Nichols, Y.C. Yang, J. Cregg, C.J. Schulze, Z. Wang, R. Dua, J. Jiang, L.S. Garrenton, N. Nasholm, A. Bermingham, J.E. Knox, K. Seamon, M. Longhi, K.-J. Chou, S. Li, D.P. Wildes, M. Singh, E.S. Koltun, A.L. Gill, J.A.M. Smith, Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers, Cancer Res 82 (2022) 3595–3595. https://doi.org/10.1158/1538-7445.AM2022-3595.
[19] J. Hallin, V. Bowcut, A. Calinisan, D.M. Briere, L. Hargis, L.D. Engstrom, J. Laguer, J. Medwid, D. Vanderpool, E. Lifset, D. Trinh, N. Hoffman, X. Wang, J. David Lawson, R.J. Gunn, C.R. Smith, N.C. Thomas, M. Martinson, A. Bergstrom, F. Sullivan, K. Bouhana, S. Winski, L. He, J. Fernandez-Banet, A. Pavlicek, J.R. Haling, L. Rahbaek, M.A. Marx, P. Olson, J.G. Christensen, Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor, Nature Medicine 2022 28:10 28 (2022) 2171–2182. https://doi.org/10.1038/s41591-022-02007-7.
[20] E. Koltun, J. Cregg, M.A. Rice, D.M. Whalen, R. Freilich, J. Jiang, R. Hansen, A. Bermingham, J.E. Knox, J. Dinglasan, K. Seamon, C. Blaj, S.S. Chang, Y. Liu, J. Huang, K.-J. Chou, L. McDowell, B.J. Lee, D. Wildes, Z. Wang, M. Singh, A.L. Gill, J.A. Smith, Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers, Cancer Res 81 (2021) 1260–1260. https://doi.org/10.1158/1538-7445.AM2021-1260.
[21] J. Hallin, L.D. Engstrom, L. Hargi, A. Calinisan, R. Aranda, D.M. Briere, N. Sudhakar, V. Bowcut, B.R. Baer, J.A. Ballard, M.R. Burkard, J.B. Fell, J.P. Fischer, G.P. Vigers, Y. Xue, S. Gatto, J. Fernandez-Banet, A. Pavlicek, K. Velastagui, R.C. Chao, J. Barton, M. Pierobon, E. Baldelli, E.F. Patricoin, D.P. Cassidy, M.A. Marx, I.I. Rybkin, M.L. Johnson, S.H. Ignatius, P. Lito, K.P. Papadopoulos, P.A. Jänne, P. Olson, J.G. Christensen, The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients, Cancer Discov 10 (2020) 54. https://doi.org/10.1158/2159-8290.CD-19-1167.
[22] M.G. Fakih, S. Kopetz, Y. Kuboki, T.W. Kim, P.N. Munster, J.C. Krauss, G.S. Falchook, S.W. Han, V. Heinemann, K. Muro, J.H. Strickler, D.S. Hong, C.S. Denlinger, G. Girotto, M.A. Lee, H. Henary, Q. Tran, J.K. Park, G. Ngarmchamnanrith, H. Prenen, T.J. Price, Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial, Lancet Oncol 23 (2022) 115–124. https://doi.org/10.1016/S1470-2045(21)00605-7.
[23] T.S. Bekaii-Saab, R. Yaeger, A.I. Spira, M.S. Pelster, J.K. Sabari, N. Hafez, M. Barve, K. Velastegui, X. Yan, A. Shetty, H. Der-Torossian, S. Pant, Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation, J Clin Oncol 41 (2023) 4097–4106. https://doi.org/10.1200/JCO.23.00434.
[24] M.L. Johnson, S.H.I. Ou, M. Barve, I.I. Rybkin, K.P. Papadopoulos, T.A. Leal, K. Velastegui, J.G. Christensen, T. Kheoh, R.C. Chao, J. Weiss, KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation, Eur J Cancer 138 (2020) S2. https://doi.org/10.1016/s0959-8049(20)31077-7.
[25] G. De Conti, M.H. Dias, R. Bernards, Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells, Cancers (Basel) 13 (2021) 1–15. https://doi.org/10.3390/CANCERS13051118.
[26] Y. Oren, M. Tsabar, M.S. Cuoco, L. Amir-Zilberstein, H.F. Cabanos, J.C. Hütter, B. Hu, P.I. Thakore, M. Tabaka, C.P. Fulco, W. Colgan, B.M. Cuevas, S.A. Hurvitz, D.J. Slamon, A. Deik, K.A. Pierce, C. Clish, A.N. Hata, E. Zaganjor, G. Lahav, K. Politi, J.S. Brugge, A. Regev, Cycling cancer persister cells arise from lineages with distinct programs, Nature 2021 596:7873 596 (2021) 576–582. https://doi.org/10.1038/s41586-021-03796-6.
[27] T. Müller, M. Kalxdorf, D.N. Rémiazdal, A. Krijgsveld, Automated sample preparation with SP3 for low-input clinical proteomics, Molecular System Biology (2020).
[28] C.S. Hughes, S. Moggridge, T. Müller, P.H. Sorensen, G.B. Morin, J. Krijgsveld, Single-pot, solid-phase-enhanced sample preparation for proteomics experiments, Nat Protoc 14 (2019) 68–85. https://doi.org/10.1038/s41596-018-0082-x.
[29] Histone western blot protocol | abcam, (n.d.). https://www.abcam.com/en-pt/technical-resources/protocols/histone-western-blot (accessed November 29, 2023).
[30] N.C. Durand, M.S. Shamim, I. Machol, S.S.P. Rao, M.H. Huntley, E.S. Lander, E.L. Aiden, Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments, Cell Syst 3 (2016) 95. https://doi.org/10.1016/J.CELS.2016.07.002.
[31] A. Singh, M.F. Sweeney, M. Yu, A. Burger, P. Greninger, C. Benes, D.A. Haber, J. Settleman, TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers, Cell 148 (2012) 639–650. https://doi.org/10.1016/J.CELL.2011.12.033.
[32] A.J. Wiecek, S.J. Cutty, D. Kornai, M. Parreno-Centeno, L.E. Gourmet, G.M. Tagliazucchi, D.H. Jacobson, P. Zhang, L. Xiong, G.L. Bond, A.R. Barr, M. Secrier, Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer, Genome Biol 24 (2023). https://doi.org/10.1186/S13059-023-02963-4.
[33] F. Ciabrelli, G. Cavalli, Chromatin-Driven Behavior of Topologically Associating Domains, J Mol Biol 427 (2015) 608–625. https://doi.org/10.1016/J.JMB.2014.09.013.
[34] S.S.P. Rao, M.H. Huntley, N.C. Durand, E.K. Stamenova, I.D. Bochkov, J.T. Robinson, A.L. Sanborn, I. Machol, A.D. Omer, E.S. Lander, E.L. Aiden, A three-dimensional map of the human genome at kilobase resolution reveals principles of chromatin looping, Cell 159 (2014) 1665. https://doi.org/10.1016/J.CELL.2014.11.021.
[35] E. Lieberman-Aiden, N.L. Van Berkum, L. Williams, M. Imakaev, T. Ragoczy, A. Telling, I. Amit, B.R. Lajoie, P.J. Sabo, M.O. Dorschner, R. Sandstrom, B. Bernstein, M.A. Bender, M. Groudine, A. Gnirke, J. Stamatoyannopoulos, L.A. Mirny, E.S. Lander, J. Dekker, Comprehensive mapping of long-range interactions reveals folding principles of the human genome, Science (1979) 326 (2009) 289–293. https://doi.org/10.1126/SCIENCE.1181369/SUPPL_FILE/LIEBERMAN-AIDEN.SOM.PDF.
[36] Y. Li, A. Eshein, R.K.A. Virk, A. Eid, W. Wu, J. Frederick, D. VanDerway, S. Gladstein, K. Huang, N.M. Anthony, G.M. Bauer, X. Zhou, V. Agrawal, E.M. Pujadas, G. Esteve, J.E. Chandler, R. Bleher, J.J. de Pablo, I. Szleifer, V.P. Dravid, L.M. Almassalha, V. Backman, Nanoscale Chromatin Imaging and Analysis (nano-ChIA) platform bridges 4-D chromatin organization with molecular function, BioRxiv (2020) 2020.01.26.920363. https://doi.org/10.1101/2020.01.26.920363.
[37] Y. Li, V. Agrawal, R.K.A. Virk, E. Roth, W.S. Li, A. Eshein, J. Frederick, K. Huang, L. Almassalha, R. Bleher, M.A. Carignano, I. Szleifer, V.P. Dravid, V. Backman, Analysis of three-dimensional chromatin packing domains by chromatin scanning transmission electron microscopy (ChromSTEM), Scientific Reports 2022 12:1 12 (2022) 1–15. https://doi.org/10.1038/s41598-022-16028-2.
[38] R.K.A. Virk, W. Wu, L.M. Almassalha, G.M. Bauer, Y. Li, D. VanDerway, J. Frederick, D. Zhang, A. Eshein, H.K. Roy, I. Szleifer, V. Backman, Disordered chromatin packing regulates phenotypic plasticity, Sci Adv 6 (2020). https://doi.org/10.1126/SCIADV.AAX6232.
[39] X. Wang, V. Agrawal, C.L. Dunton, Y. Liu, R.K.A. Virk, P.A. Patel, L. Carter, E.M. Pujadas, Y. Li, S. Jain, H. Wang, N. Ni, H.M. Tsai, N. Rivera-Bolanos, J. Frederick, E. Roth, R. Bleher, C. Duan, P. Ntziachristos, T.C. He, R.R. Reid, B. Jiang, H. Subramanian, V. Backman, G.A. Ameer, Chromatin reprogramming and bone regeneration in vitro and in vivo via the microtopography-induced constriction of cell nuclei, Nature Biomedical Engineering 2023 7:11 7 (2023) 1514–1529. https://doi.org/10.1038/s41551-023-01053-x.
[40] A. Biswas, S. Sahoo, G.M. Riedlinger, S. Ghodoussipour, M.K. Jolly, S. De, Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma, Communications Biology 2023 6:1 6 (2023) 1–18. https://doi.org/10.1038/s42003-023-05668-3.
[41] A.J. Sabnis, T.G. Bivona, Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology, Trends Mol Med 25 (2019) 185–197. https://doi.org/10.1016/J.MOLMED.2018.12.009.
[42] D.S. Hong, M.G. Fakih, J.H. Strickler, J. Desai, G.A. Durm, G.I. Shapiro, G.S. Falchook, T.J. Price, A. Sacher, C.S. Denlinger, Y.-J. Bang, G.K. Dy, J.C. Krauss, Y. Kuboki, J.C. Kuo, A.L. Coveler, K. Park, T.W. Kim, F. Barlesi, P.N. Munster, S.S. Ramalingam, T.F. Burns, F. Meric-Bernstam, H. Henary, J. Ngang, G. Ngarmchamnanrith, J. Kim, B.E. Houk, J. Canon, J.R. Lipford, G. Friberg, P. Lito, R. Govindan, B.T. Li, KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors , New England Journal of Medicine 383 (2020) 1207–1217. https://doi.org/10.1056/NEJMOA1917239/SUPPL_FILE/NEJMOA1917239_DATA-SHARING.PDF.
[43] Z. Mao, H. Xiao, P. Shen, Y. Yang, J. Xue, Y. Yang, Y. Shang, L. Zhang, X. Li, Y. Zhang, Y. Du, C.C. Chen, R.T. Guo, Y. Zhang, KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge, Cell Discovery 2022 8:1 8 (2022) 1–14. https://doi.org/10.1038/s41421-021-00368-w.
[44] J.Y. Xue, Y. Zhao, J. Aronowitz, T.T. Mai, A. Vides, B. Qeriqi, D. Kim, C. Li, E. de Stanchina, L. Mazutis, D. Risso, P. Lito, Rapid non-uniform adaptation to conformation-specific KRASG12C inhibition, Nature 577 (2020) 421. https://doi.org/10.1038/S41586-019-1884-X.
[45] C.K. Stubbs, M. Biancucci, V. Vidimar, K.J.F. Satchell, RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines, Sci Rep 11 (2021) 17925. https://doi.org/10.1038/S41598-021-97422-0.
[46] H.F. Cabanos, A.N. Hata, Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer, Cancers 2021, Vol. 13, Page 2666 13 (2021) 2666. https://doi.org/10.3390/CANCERS13112666.
[47] L.M. Almassalha, G.M. Bauer, W. Wu, L. Cherkezyan, D. Zhang, A. Kendra, S. Gladstein, J.E. Chandler, D. Vanderway, B.L.L. Seagle, A. Ugolkov, D.D. Billadeau, T. V. O’Halloran, A.P. Mazar, H.K. Roy, I. Szleifer, S. Shahabi, V. Backman, Macrogenomic engineering via modulation of the scaling of chromatin packing density, Nature Biomedical Engineering 2017 1:11 1 (2017) 902–913. https://doi.org/10.1038/s41551-017-0153-2.